7,500,000 Units Biotech Group Acquisition Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks • New York
Contract Type FiledMay 26th, 2022 Company Industry JurisdictionThe undersigned, Biotech Group Acquisition Corporation, a newly formed blank check company formed as a Delaware corporation (the “Company”), hereby confirms its agreement with US Tiger Securities, Inc (“US Tiger,” or the “Representative”) and with the other underwriters named on Schedule A hereto for which you are acting as representative (the Representative and the other Underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”), as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks • New York
Contract Type FiledMay 26th, 2022 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2022, is made and entered into by and among Biotech Group Acquisition Corporation, a Delaware corporation (the “Company”), Biotech Group Acquisition Sponsor LLC, a Delaware limited liability company (the “Sponsor”), Yiru (Melody) Shi, Manu Ohri, John Brugmann, Jingmin Rogers, and Yi Wung (together with the Sponsor, the “Founders”), and US Tiger Securities, Inc. (“US Tiger”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks • New York
Contract Type FiledMay 26th, 2022 Company Industry JurisdictionThis Agreement is made effective as of [____], 2022 by and between Biotech Group Acquisition Corporation (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”).
Biotech Group Acquisition Corporation 2400 Barranca Pkwy, Suite 300 Irvine, CA 92606Underwriting Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks
Contract Type FiledMay 26th, 2022 Company IndustryThis letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and between among Biotech Group Acquisition Corporation, a Delaware corporation (the “Company”), and US Tiger Securities, Inc. (“US Tiger”), relating to an underwritten initial public offering (the “Public Offering”), of up to 7,500,000 of the Company’s units (including up to 1,125,000 units that may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one share of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), and one redeemable warrant. Each Warrant (each, a “Warrant”) entitles the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per share, subject to adjustment. The Units shall be sold in the Public Offering pursuant to a registration statement on Form S-1 and prospectus (the “Prospectus”) filed by the Company with th
PRIVATE UNIT SUBSCRIPTION AGREEMENT BETWEEN THE REGISTRANT AND THE SPONSORPrivate Unit Subscription Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks
Contract Type FiledMay 26th, 2022 Company Industry
WARRANT AGREEMENTWarrant Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks • New York
Contract Type FiledMay 26th, 2022 Company Industry JurisdictionThis WARRANT AGREEMENT (this “Agreement”) is made as of [●], 2022 between Biotech Group Acquisition Corporation, a Delaware corporation, with offices at 2400 Barranca Pkwy, Suite 300, Irvine, CA 92606 (“Company”), and Continental Stock Transfer & Trust Company, a New York company, with offices at 1 State Street, 30th Floor, New York, NY 10004, as warrant agent (“Warrant Agent”).
SHARE SURRENDER AGREEMENTShare Surrender Agreement • May 26th, 2022 • Biotech Group Acquisition Corp • Blank checks • New York
Contract Type FiledMay 26th, 2022 Company Industry JurisdictionTHIS SHARE SURRENDER AGREEMENT (this “Agreement”) is made as of May 19, 2022, by and among Biotech Group Acquisition Corporation, a Delaware corporation (the “Company”), Biotech Group Acquisition Sponsor LLC, a Delaware limited liability company (“Sponsor”), Yiru Shi, an individual (“Shi”), and Manu Ohri, an individual (“Ohri” and together with Sponsor and Shi, the “Stockholders” and each, a “Stockholder”).